PRECISION GENE THERAPY FOR CANCER IMMUNOTHERAPY
TOWARDS TO SAFER AND MORE EFFICIENT ADVANCED THERAPIES
Our Mission
Our MISSION is to develop new technologies to improve the efficacy and safety of cancer immunotherapy (CAR-T cells).
LentiStem Biotech is committed to providing innovative molecular tools for the optimization of advanced therapies, ensuring the highest standards of safety and clinical efficacy.
Safety
Developing vectors that minimize off-target effects and improve patient safety profiles.
Efficiency
Optimizing transduction rates and expression precision for better therapeutic outcomes.
Challenges in CAR-T Cell Therapy
Current advanced therapies face significant hurdles that Lentistem is actively working to overcome through innovative genetic engineering.
Lack of Efficacy
Addressing the limitations in therapeutic response for various cancer types.
Severe Toxicities
Reducing side effects to make advanced therapies safer for all patients.
Long Manufacturing
Optimizing production times to deliver life-saving treatments faster.
Our Technological Solutions
We have developed proprietary platforms to redesign how genetic material is delivered and regulated within therapeutic cells.
Explore PipelineOur Pipeline
| Candidate | Indication | Phase | Status |
|---|---|---|---|
| LS-CAR-01 | Hematological Malignancies (CD19+) | Pre-clinical | Active |
| LS-CAR-02 | Solid Tumors (TCR-like) | Discovery | In Progress |
LentiStem Biotech is building a diversified pipeline of enhanced and safer CAR-T candidates.
Latest Publications
View All News
Lentistem Biotech is an R&D biotechnology company which designs and produces therapeutic lentiviral vectors. Our MISSION is to develop new technologies to improve the efficacy and safety of cancer immunotherapy (CAR-T cells).
Subscribe to our newsletter
Av. de la Ilustración, 114 (Genyo Building), 18007, Granada
Contact with us
- Av. de la Ilustración, 114 (Genyo Building), 18007, Granada
- info@lentistem.com
LentiStem Biotech is committed to advancing the future of immunotherapy. Reach out to learn more about our collaborations and technology.